Cansino Biologics Stock Performance
| CASBF Stock | USD 3.88 0.12 3.00% |
On a scale of 0 to 100, CanSino Biologics holds a performance score of 5. The firm shows a Beta (market volatility) of -0.27, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning CanSino Biologics are expected to decrease at a much lower rate. During the bear market, CanSino Biologics is likely to outperform the market. Please check CanSino Biologics' kurtosis, and the relationship between the treynor ratio and rate of daily change , to make a quick decision on whether CanSino Biologics' price patterns will revert.
Risk-Adjusted Performance
5 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in CanSino Biologics are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Despite nearly unsteady fundamental drivers, CanSino Biologics reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 4.4 B | |
| Total Cashflows From Investing Activities | -2.6 B |
CanSino |
CanSino Biologics Relative Risk vs. Return Landscape
If you would invest 351.00 in CanSino Biologics on October 9, 2024 and sell it today you would earn a total of 37.00 from holding CanSino Biologics or generate 10.54% return on investment over 90 days. CanSino Biologics is currently producing 0.2124% returns and takes up 3.2127% volatility of returns over 90 trading days. Put another way, 28% of traded pink sheets are less volatile than CanSino, and 96% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
CanSino Biologics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for CanSino Biologics' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as CanSino Biologics, and traders can use it to determine the average amount a CanSino Biologics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0661
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | CASBF | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.21 actual daily | 28 72% of assets are more volatile |
Expected Return
| 0.21 actual daily | 4 96% of assets have higher returns |
Risk-Adjusted Return
| 0.07 actual daily | 5 95% of assets perform better |
Based on monthly moving average CanSino Biologics is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of CanSino Biologics by adding it to a well-diversified portfolio.
CanSino Biologics Fundamentals Growth
CanSino Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of CanSino Biologics, and CanSino Biologics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on CanSino Pink Sheet performance.
| Return On Equity | 0.0111 | |||
| Return On Asset | -0.0207 | |||
| Profit Margin | 0.06 % | |||
| Operating Margin | (0.19) % | |||
| Current Valuation | 3.58 B | |||
| Shares Outstanding | 114.78 M | |||
| Price To Earning | 19.25 X | |||
| Price To Book | 2.30 X | |||
| Price To Sales | 2.51 X | |||
| Revenue | 4.3 B | |||
| EBITDA | 2.05 B | |||
| Cash And Equivalents | 7 B | |||
| Cash Per Share | 28.36 X | |||
| Total Debt | 40 M | |||
| Debt To Equity | 0.26 % | |||
| Book Value Per Share | 29.22 X | |||
| Cash Flow From Operations | 2.05 B | |||
| Earnings Per Share | 0.59 X | |||
| Total Asset | 11.87 B | |||
About CanSino Biologics Performance
By analyzing CanSino Biologics' fundamental ratios, stakeholders can gain valuable insights into CanSino Biologics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if CanSino Biologics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if CanSino Biologics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the Peoples Republic of China. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the Peoples Republic of China. Cansino Biologics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 2191 people.Things to note about CanSino Biologics performance evaluation
Checking the ongoing alerts about CanSino Biologics for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for CanSino Biologics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| CanSino Biologics had very high historical volatility over the last 90 days | |
| About 27.0% of the company shares are held by company insiders |
- Analyzing CanSino Biologics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether CanSino Biologics' stock is overvalued or undervalued compared to its peers.
- Examining CanSino Biologics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating CanSino Biologics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of CanSino Biologics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of CanSino Biologics' pink sheet. These opinions can provide insight into CanSino Biologics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for CanSino Pink Sheet analysis
When running CanSino Biologics' price analysis, check to measure CanSino Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CanSino Biologics is operating at the current time. Most of CanSino Biologics' value examination focuses on studying past and present price action to predict the probability of CanSino Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CanSino Biologics' price. Additionally, you may evaluate how the addition of CanSino Biologics to your portfolios can decrease your overall portfolio volatility.
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |